<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01112033</url>
  </required_header>
  <id_info>
    <org_study_id>BLVRA1</org_study_id>
    <nct_id>NCT01112033</nct_id>
  </id_info>
  <brief_title>Biliverdin Reductase A in Chronic Hepatitis C Virus Infection</brief_title>
  <official_title>Biliverdin Reductase A in Chronic Hepatitis C Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charles University, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Military University Hospital, Prague</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General University Hospital, Prague</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute for Clinical and Experimental Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charles University, Czech Republic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this project, the investigators aim to study the role of biliverdin reductase A (BLVRA) in
      HCV infected patients prior and during/after standard antiviral therapy in association with
      viral clearance, disease progression and treatment response and in comparison with healthy
      subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To analyze biliverdin reductase (BLVRA) expression in the liver of HVC infected patients
           undergoing liver biopsy followed by standard antiviral treatment (peg-interferon plus
           ribavirin combination therapy) and patients with other forms of liver diseases
           undergoing liver biopsy as controls.

        2. To analyze BLVRA expression in peripheral blood leukocytes (PBL) of therapeutically
           naïve HCV patients, during/after standard antiviral therapy and healthy controls.

        3. To analyze BVLRA genetic polymorphisms both in HCV infected patients and healthy
           controls.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To assess differences in BLVRA expression in the liver and PBMC in HCV infected patients in responders and non-responders to standard antiviral therapy.</measure>
    <time_frame>72 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To analyze the association of genetic polymorphisms of BLVRA with disease progression and treatment response in HCV infected patients.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">113</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>chronic HCV infection</arm_group_label>
    <description>The study was performed on therapeutically naïve patients with chronic HCV infection. Patients with positivity of anti-HCV antibodies, and detectable HCV RNA in serum for at least 6 months, were included in the study.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      peripheral blood, liver biopsy
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Estimated enrollment: BLVRA expression study: 50 - 100 HCV patients 50 healthy volunteers
        Polymorphisms of BLVRA study: 300 HCV patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        BLVRA expression study

          -  Therapeutically naïve HCV patients undergoing antiviral treatment with peg-interferon
             plus ribavirin combination therapy

        BLVRA genetic polymorphisms study

          -  HCV infected patients prior, during, after or without antiviral therapy

        Exclusion Criteria:

          -  Co-infection with HAV, HBV and HIV

          -  Disorders of heme metabolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iva Subhanova</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charles University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University in Prague</name>
      <address>
        <city>Prague</city>
        <zip>128 60</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <results_reference>
    <citation>Subhanova I, Muchova L, Lenicek M, Vreman HJ, Luksan O, Kubickova K, Kreidlova M, Zima T, Vitek L, Urbanek P. Expression of Biliverdin Reductase A in peripheral blood leukocytes is associated with treatment response in HCV-infected patients. PLoS One. 2013;8(3):e57555. doi: 10.1371/journal.pone.0057555. Epub 2013 Mar 11.</citation>
    <PMID>23536765</PMID>
  </results_reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2010</study_first_submitted>
  <study_first_submitted_qc>April 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2010</study_first_posted>
  <last_update_submitted>August 5, 2015</last_update_submitted>
  <last_update_submitted_qc>August 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charles University, Czech Republic</investigator_affiliation>
    <investigator_full_name>Iva Subhanova</investigator_full_name>
    <investigator_title>Institute of Medical Biochemistry and Laboratory Diagnostics</investigator_title>
  </responsible_party>
  <keyword>biliverdin reductase</keyword>
  <keyword>BLVRA</keyword>
  <keyword>hepatitis C</keyword>
  <keyword>HCV</keyword>
  <keyword>peripheral blood mononuclear cells</keyword>
  <keyword>PBMC</keyword>
  <keyword>liver</keyword>
  <keyword>genetic polymorphisms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

